Systemic lupus erythematosus: Updates from EULAR 2020
A number of studies presented at the European League Against Rheumatism E-Congress 2020 (EULAR 2020) have a potential to impact the management of systemic lupus erythematosus (SLE) in the clinic. One phase II study showed that withdrawal of mycophenolate mofetil (MMF) may be safe in quiescent SLE, while a phase III trial demonstrated efficacy and tolerability of the B-lymphocyte stimulator (BLyS) inhibitor belimumab in SLE patients with lupus nephritis (LN). Experts also discussed how latest evidence on early intervention and disease activity assessment can be incorporated into clinical practice.

New Molecule

4 New

New Formulation

2 New

New Indication

5 New

Color 1
Color 2
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in